Industry Urges EU To Up Its Game On Manufacturing
Medicines For Europe Demands ‘Tailored Actions’ As Part Of Industrial Strategy
While the European off-patent industry has welcomed the latest update to the EU’s industrial strategy, including a detailed analysis of European dependencies on the global API manufacturing network, it has urged the European Commission to go further and provide “tailored actions” to bolster local manufacturing.
You may also be interested in...
Generic and biosimilar medicines must become central to European healthcare policy as the region looks to rebuild in the wake of the COVID-19 pandemic, Medicines for Europe’s new president, Rebecca Guntern of Sandoz, tells Generics Bulletin in an exclusive interview.
As part of a “structured dialog” initiated with pharmaceutical industry stakeholders by the European Commission, local off-patent industry association Medicines for Europe has set out the key reforms needed to bolster the sector.
Ahead of an upcoming European Council meeting covering the EU’s industrial policy and ongoing response to the COVID-19 pandemic, Medicines for Europe has set out what it sees as key policy objectives to consider.